NASDAQ : CLDX
Celldex Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 30.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.36B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.28B |
| Enterprise Value | 1.57B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 78.53M |
| Shares Outstanding | 78.53M |
| Shares Change (YoY) | +4.49% |
| Shares Change (QoQ) | +16.94% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 110.55% |
| Float | 73.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14,433.53 |
| Forward PS | 909.72 |
| PB Ratio | 3.19 |
| P/TBV Ratio | 3.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 9,922.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.82 |
| Quick Ratio | 11.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -43.88% |
| Return on Assets (ROA) | -27.62% |
| Return on Invested Capital (ROIC) | -29.56% |
| Return on Capital Employed (ROCE) | -45.19% |
| Weighted Average Cost of Capital (WACC) | 9.87% |
| Revenue Per Employee | $798 |
| Profits Per Employee | -$1.52M |
| Employee Count | 198 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +8.64% |
| 50-Day Moving Average | 33.83 |
| 200-Day Moving Average | 32.67 |
| Relative Strength Index (RSI) | 40.68 |
| Average Volume (20 Days) | 1,242,829 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.60M |
| Short Previous Month | 11.01M |
| Short % of Shares Out | 12.22% |
| Short % of Float | 13.15% |
| Short Ratio (days to cover) | 4.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 158,000 |
| Gross Profit | -278.65M |
| Operating Income | -325.83M |
| Pretax Income | -300.55M |
| Net Income | -300.55M |
| EBITDA | -322.43M |
| EBIT | -325.83M |
| Loss Per Share | -$4.33 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 717.59M |
| Total Debt | 4.90M |
| Net Cash | 712.68M |
| Net Cash Per Share | $9.08 |
| Equity (Book Value) | 714.56M |
| Book Value Per Share | 9.10 |
| Working Capital | 663.61M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -235.57M |
| Capital Expenditures | -6.54M |
| Depreciation & Amortization | 3.40M |
| Net Borrowing | n/a |
| Free Cash Flow | -242.11M |
| FCF Per Share | -$3.08 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -206,220.25% |
| Pretax Margin | -190,220.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.49% |
| Shareholder Yield | -4.49% |
| Earnings Yield | -14.92% |
| FCF Yield | -10.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $63.07 |
| Price Target Difference | 117.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 329.78% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 12.97 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |